Proteasome activation: An innovative promising approach for delaying aging and retarding age-related diseases

Ageing Research Reviews

Volumn 23, Issue PA, 2015, Pages 37-55

  Chondrogianni, Niki ^a   Voutetakis, Konstantinos ^a   Kapetanou, Marianna ^a   Delitsikou, Vasiliki ^a   Papaevgeniou, Nikoletta ^a   Sakellari, Marianthi ^a,b   Lefaki, Maria ^a   Filippopoulou, Konstantina ^a   Gonos, Efstathios S ^a,b  

^a INSTITUTE OF BIOLOGY   (Greece)

^b ÖREBRO UNIVERSITY   (Sweden)

Author keywords

Age related diseases; Aging; Longevity; Proteasome activation; Senescence; Ubiquitin proteasome system

Indexed keywords

ADENOSINE TRIPHOSPHATASE; CURCUMIN; FLAVONOID; OLEUROPEIN; PHENOL DERIVATIVE; PROTEASOME; TRANSCRIPTION FACTOR NRF2; UBIQUITIN; UBIQUITIN PROTEIN LIGASE E3;

AGING; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTIGEN PRESENTATION; ANTIOXIDANT ACTIVITY; ARTICLE; CAENORHABDITIS ELEGANS; CALORIC RESTRICTION; DROSOPHILA MELANOGASTER; ENZYME CONFORMATION; GENE OVEREXPRESSION; HUMAN; HUNTINGTON CHOREA; KERATINOCYTE; LONGEVITY; MAMMAL CELL; OXIDATIVE STRESS; PARKINSON DISEASE; POLLEN; PROGERIA; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN SUBUNIT; RODENT; SACCHAROMYCES CEREVISIAE; UBIQUITINATION; ANIMAL; DRUG EFFECTS; GENETICS; GERIATRICS; METABOLISM; NERVOUS SYSTEM DISEASES; TRANSCRIPTION INITIATION;

AGING; ANIMALS; GERIATRICS; HUMANS; LONGEVITY; NERVOUS SYSTEM DISEASES; PROTEASOME ENDOPEPTIDASE COMPLEX; TRANSCRIPTIONAL ACTIVATION;

EID: 84931570247     PISSN: 15681637     EISSN: 18729649     Source Type: Journal    
DOI: 10.1016/j.arr.2014.12.003     Document Type: Review

References (266)

1. Ahtoniemi T., Goldsteins G., Keksa-Goldsteine V., Malm T., Kanninen K., Salminen A., Koistinaho J. Pyrrolidine dithiocarbamate inhibits induction of immunoproteasome and decreases survival in a rat model of amyotrophic lateral sclerosis. Mol. Pharmacol. 2007, 71:30-37.
2. Ajroud-Driss S., Siddique T. Sporadic and hereditary amyotrophic lateral sclerosis (ALS). Biochim. Biophys. Acta 2014.
3. Ali R.E., Rattan S.I. Curcumin's biphasic hormetic response on proteasome activity and heat-shock protein synthesis in human keratinocytes. Ann. N. Y. Acad. Sci. 2006, 1067:394-399.
4. Alpi A.F., Patel K.J. Monoubiquitylation in the Fanconi anemia DNA damage response pathway. DNA Repair (Amst.) 2009, 8:430-435.
5. Andersson V., Hanzen S., Liu B., Molin M., Nystrom T. Enhancing protein disaggregation restores proteasome activity in aged cells. Aging (Albany, NY) 2013, 5:802-812.
6. Arima K., Kinoshita A., Mishima H., Kanazawa N., Kaneko T., Mizushima T., Ichinose K., Nakamura H., Tsujino A., Kawakami A., Matsunaka M., Kasagi S., Kawano S., Kumagai S., Ohmura K., Mimori T., Hirano M., Ueno S., Tanaka K., Tanaka M., Toyoshima I., Sugino H., Yamakawa A., Niikawa N., Furukawa F., Murata S., Eguchi K., Ida H., Yoshiura K. Proteasome assembly defect due to a proteasome subunit beta type 8 (PSMB8) mutation causes the autoinflammatory disorder, Nakajo-Nishimura syndrome. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:14914-14919.
7. Bader M., Benjamin S., Wapinski O.L., Smith D.M., Goldberg A.L., Steller H. A conserved F box regulatory complex controls proteasome activity in Drosophila. Cell 2011, 145:371-382.
8. Bajorek M., Finley D., Glickman M.H. Proteasome disassembly and downregulation is correlated with viability during stationary phase. Curr. Biol.: CB 2003, 13:1140-1144.
9. Baraibar M.A., Friguet B. Chapter 7 - changes of the proteasomal system during the aging process. Progress in Molecular Biology and Translational Science 2012, 249-275. Academic Press. G. Tilman (Ed.).
10. Barros M.H., Bandy B., Tahara E.B., Kowaltowski A.J. Higher respiratory activity decreases mitochondrial reactive oxygen release and increases life span in Saccharomyces cerevisiae. J. Biol. Chem. 2004, 279:49883-49888.
11. Basso M., Massignan T., Samengo G., Cheroni C., De Biasi S., Salmona M., Bendotti C., Bonetto V. Insoluble mutant SOD1 is partly oligoubiquitinated in amyotrophic lateral sclerosis mice. J. Biol. Chem. 2006, 281:33325-33335.
12. Bauer P.O., Nukina N. Enhanced degradation of mutant huntingtin by rho kinase inhibition is mediated through activation of proteasome and macroautophagy. Autophagy 2009, 5:747-748.
13. Bedford L., Hay D., Devoy A., Paine S., Powe D.G., Seth R., Gray T., Topham I., Fone K., Rezvani N., Mee M., Soane T., Layfield R., Sheppard P.W., Ebendal T., Usoskin D., Lowe J., Mayer R.J. Depletion of 26S proteasomes in mouse brain neurons causes neurodegeneration and Lewy-like inclusions resembling human pale bodies. J. Neurosci.: Off. J. Soc. Neurosci. 2008, 28:8189-8198.
14. Bendotti C., Marino M., Cheroni C., Fontana E., Crippa V., Poletti A., De Biasi S. Dysfunction of constitutive and inducible ubiquitin-proteasome system in amyotrophic lateral sclerosis: implication for protein aggregation and immune response. Prog. Neurobiol. 2012, 97:101-126.
15. Bennett E.J., Bence N.F., Jayakumar R., Kopito R.R. Global impairment of the ubiquitin-proteasome system by nuclear or cytoplasmic protein aggregates precedes inclusion body formation. Mol. Cell 2005, 17:351-365.
16. Bennett E.J., Shaler T.A., Woodman B., Ryu K.Y., Zaitseva T.S., Becker C.H., Bates G.P., Schulman H., Kopito R.R. Global changes to the ubiquitin system in Huntington's disease. Nature 2007, 448:704-708.
17. Bergink S., Jentsch S. Principles of ubiquitin and SUMO modifications in DNA repair. Nature 2009, 458:461-467.
18. Beyer K., Domingo-Sabat M., Ariza A. Molecular pathology of Lewy body diseases. Int. J. Mol. Sci. 2009, 10:724-745.
19. Bodner R.A., Outeiro T.F., Altmann S., Maxwell M.M., Cho S.H., Hyman B.T., McLean P.J., Young A.B., Housman D.E., Kazantsev A.G. Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:4246-4251.
20. Bohgaki M., Bohgaki T., El Ghamrasni S., Srikumar T., Maire G., Panier S., Fradet-Turcotte A., Stewart G.S., Raught B., Hakem A., Hakem R. RNF168 ubiquitylates 53BP1 and controls its response to DNA double-strand breaks. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:20982-20987.
21. Bulteau A.L., Moreau M., Nizard C., Friguet B. Impairment of proteasome function upon UVA- and UVB-irradiation of human keratinocytes. Free Radic. Biol. Med. 2002, 32:1157-1170.
22. Bulteau A.L., Moreau M., Saunois A., Nizard C., Friguet B. Algae extract-mediated stimulation and protection of proteasome activity within human keratinocytes exposed to UVA and UVB irradiation. Antioxid. Redox Signal. 2006, 8:136-143.
23. Bulteau A.L., Petropoulos I., Friguet B. Age-related alterations of proteasome structure and function in aging epidermis. Exp. Gerontol. 2000, 35:767-777.
24. Burkewitz K., Choe K.P., Lee E.C., Deonarine A., Strange K. Characterization of the proteostasis roles of glycerol accumulation, protein degradation and protein synthesis during osmotic stress in C. elegans. PLoS ONE 2012, 7:e34153.
25. Cabreiro F., Perichon M., Jatje J., Malavolta M., Mocchegiani E., Friguet B., Petropoulos I. Zinc supplementation in the elderly subjects: effect on oxidized protein degradation and repair systems in peripheral blood lymphocytes. Exp. Gerontol. 2008, 43:483-487.
26. Campos M.G., Webby R.F., Markham K.R., Mitchell K.A., Da Cunha A.P. Age-induced diminution of free radical scavenging capacity in bee pollens and the contribution of constituent flavonoids. J. Agric. Food Chem. 2003, 51:742-745.
27. Carrano A.C., Liu Z., Dillin A., Hunter T. A conserved ubiquitination pathway determines longevity in response to diet restriction. Nature 2009, 460:396-399.
28. Carrard G., Dieu M., Raes M., Toussaint O., Friguet B. Impact of ageing on proteasome structure and function in human lymphocytes. Int. J. Biochem. Cell Biol. 2003, 35:728-739.
29. Chakrabortee S., Liu Y., Zhang L., Matthews H.R., Zhang H., Pan N., Cheng C.R., Guan S.H., Guo D.A., Huang Z., Zheng Y., Tunnacliffe A. Macromolecular and small-molecule modulation of intracellular Abeta42 aggregation and associated toxicity. Biochem. J. 2012, 442:507-515.
30. Chen Q., Thorpe J., Ding Q., El-Amouri I.S., Keller J.N. Proteasome synthesis and assembly are required for survival during stationary phase. Free Radic. Biol. Med. 2004, 37:859-868.
31. Chen Q., Thorpe J., Dohmen J.R., Li F., Keller J.N. Ump1 extends yeast lifespan and enhances viability during oxidative stress: central role for the proteasome?. Free Radic. Biol. Med. 2006, 40:120-126.
32. Cheng Y.F., Zhu G.Q., Wang M., Cheng H., Zhou A., Wang N., Fang N., Wang X.C., Xiao X.Q., Chen Z.W., Li Q.L. Involvement of ubiquitin proteasome system in protective mechanisms of Puerarin to MPP(+)-elicited apoptosis. Neurosci. Res. 2009, 63:52-58.
33. Cheroni C., Marino M., Tortarolo M., Veglianese P., De Biasi S., Fontana E., Zuccarello L.V., Maynard C.J., Dantuma N.P., Bendotti C. Functional alterations of the ubiquitin-proteasome system in motor neurons of a mouse model of familial amyotrophic lateral sclerosis. Hum. Mol. Genet. 2009, 18:82-96.
34. Cheroni C., Peviani M., Cascio P., Debiasi S., Monti C., Bendotti C. Accumulation of human SOD1 and ubiquitinated deposits in the spinal cord of SOD1G93A mice during motor neuron disease progression correlates with a decrease of proteasome. Neurobiol. Dis. 2005, 18:509-522.
35. Choe K.P., Przybysz A.J., Strange K. The WD40 repeat protein WDR-23 functions with the CUL4/DDB1 ubiquitin ligase to regulate nuclear abundance and activity of SKN-1 in Caenorhabditis elegans. Mol. Cell. Biol. 2009, 29:2704-2715.
36. Choi J., Levey A.I., Weintraub S.T., Rees H.D., Gearing M., Chin L.S., Li L. Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases. J Biol Chem. 2004, 279:13256-13264.
37. Chondrogianni N., Georgila K., Kourtis N., Tavernarakis N., Gonos E.S. 20S proteasome activation promotes lifespan extension and resistance to proteotoxicity in C. elegans. FASEB J. 2015, (in press).
38. Chondrogianni N., Gonos E.S. Proteasome dysfunction in mammalian aging: steps and factors involved. Exp. Gerontol. 2005, 40:931-938.
39. Chondrogianni N., Gonos E.S. Overexpression of hUMP1/POMP proteasome accessory protein enhances proteasome-mediated antioxidant defence. Exp. Gerontol. 2007, 42:899-903.
40. Chondrogianni N., Gonos E.S. Proteasome activation as a novel antiaging strategy. IUBMB Life 2008, 60:651-655.
41. Chondrogianni N., Kapeta S., Chinou I., Vassilatou K., Papassideri I., Gonos E.S. Anti-ageing and rejuvenating effects of quercetin. Exp. Gerontol. 2010, 45:763-771.
42. Chondrogianni N., Petropoulos I., Franceschi C., Friguet B., Gonos E.S. Fibroblast cultures from healthy centenarians have an active proteasome. Exp. Gerontol. 2000, 35:721-728.
43. Chondrogianni N., Petropoulos I., Grimm S., Georgila K., Catalgol B., Friguet B., Grune T., Gonos E.S. Protein damage, repair and proteolysis. Mol. Aspects Med. 2014, 35:1-71.
44. Chondrogianni N., Sakellari M., Lefaki M., Papaevgeniou N., Gonos E.S. Proteasome activation delays aging in vitro and in vivo. Free Radic. Biol. Med. 2014, 71:303-320.
45. Chondrogianni N., Tzavelas C., Pemberton A.J., Nezis I.P., Rivett A.J., Gonos E.S. Overexpression of proteasome beta5 assembled subunit increases the amount of proteasome and confers ameliorated response to oxidative stress and higher survival rates. J. Biol. Chem. 2005, 280:11840-11850.
46. Chu-Ping M., Slaughter C.A., DeMartino G.N. Purification and characterization of a protein inhibitor of the 20S proteasome (macropain). Biochim. Biophys. Acta 1992, 1119:303-311.
47. Crossan G.P., Patel K.J. The Fanconi anaemia pathway orchestrates incisions at sites of crosslinked DNA. J. Pathol. 2012, 226:326-337.
48. Crowe E., Sell C., Thomas J.D., Johannes G.J., Torres C. Activation of proteasome by insulin-like growth factor-I may enhance clearance of oxidized proteins in the brain. Mech. Ageing Dev. 2009, 130:793-800.
49. da Cunha F.M., Demasi M., Kowaltowski A.J. Aging and calorie restriction modulate yeast redox state, oxidized protein removal, and the ubiquitin-proteasome system. Free Radic. Biol. Med. 2011, 51:664-670.
50. da Fonseca P.C., Morris E.P. Structure of the human 26S proteasome: subunit radial displacements open the gate into the proteolytic core. J. Biol. Chem. 2008, 283:23305-23314.
51. Dal Vechio F.H., Cerqueira F., Augusto O., Lopes R., Demasi M. Peptides that activate the 20S proteasome by gate opening increased oxidized protein removal and reduced protein aggregation. Free Radic. Biol. Med. 2013, 67C:304-313.
52. Dal Vechio F.H., Cerqueira F., Augusto O., Lopes R., Demasi M. Peptides that activate the 20S proteasome by gate opening increased oxidized protein removal and reduced protein aggregation. Free Radic. Biol. Med. 2014, 67:304-313.
53. Dangond F., Hwang D., Camelo S., Pasinelli P., Frosch M.P., Stephanopoulos G., Stephanopoulos G., Brown R.H., Gullans S.R. Molecular signature of late-stage human ALS revealed by expression profiling of postmortem spinal cord gray matter. Physiol. Genomics 2004, 16:229-239.
54. Davy A., Bello P., Thierry-Mieg N., Vaglio P., Hitti J., Doucette-Stamm L., Thierry-Mieg D., Reboul J., Boulton S., Walhout A.J., Coux O., Vidal M. A protein-protein interaction map of the Caenorhabditis elegans 26S proteasome. EMBO Rep. 2001, 2:821-828.
55. Dawson T.M., Ko H.S., Dawson V.L. Genetic animal models of Parkinson's disease. Neuron 2010, 66:646-661.
56. De Sandre-Giovannoli A., Bernard R., Cau P., Navarro C., Amiel J., Boccaccio I., Lyonnet S., Stewart C.L., Munnich A., Le Merrer M., Levy N. Lamin a truncation in Hutchinson-Gilford progeria. Science 2003, 300:2055.
57. Deng H.X., Shi Y., Furukawa Y., Zhai H., Fu R., Liu E., Gorrie G.H., Khan M.S., Hung W.Y., Bigio E.H., Lukas T., Dal Canto M.C., O'Halloran T.V., Siddique T. Conversion to the amyotrophic lateral sclerosis phenotype is associated with intermolecular linked insoluble aggregates of SOD1 in mitochondria. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:7142-7147.
58. Depuydt G., Xie F., Petyuk V.A., Shanmugam N., Smolders A., Dhondt I., Brewer H.M., Camp D.G., Smith R.D., Braeckman B.P. Reduced insulin/insulin-like growth factor-1 signaling and dietary restriction inhibit translation but preserve muscle mass in Caenorhabditis elegans. Mol Cell. Proteomics: MCP 2013, 12:3624-3639.
59. Diaz-Hernandez M., Hernandez F., Martin-Aparicio E., Gomez-Ramos P., Moran M.A., Castano J.G., Ferrer I., Avila J., Lucas J.J. Neuronal induction of the immunoproteasome in Huntington's disease. J. Neurosci. 2003, 23:11653-11661.
60. Diaz-Hernandez M., Valera A.G., Moran M.A., Gomez-Ramos P., Alvarez-Castelao B., Castano J.G., Hernandez F., Lucas J.J. Inhibition of 26S proteasome activity by huntingtin filaments but not inclusion bodies isolated from mouse and human brain. J. Neurochem. 2006, 98:1585-1596.
61. Ding S.L., Shen C.Y. Model of human aging: recent findings on Werner's and Hutchinson-Gilford progeria syndromes. Clin. Interv. Aging 2008, 3:431-444.
62. Eriksson M., Brown W.T., Gordon L.B., Glynn M.W., Singer J., Scott L., Erdos M.R., Robbins C.M., Moses T.Y., Berglund P., Dutra A., Pak E., Durkin S., Csoka A.B., Boehnke M., Glover T.W., Collins F.S. Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature 2003, 423:293-298.
63. Fabrizio P., Gattazzo C., Battistella L., Wei M., Cheng C., McGrew K., Longo V.D. Sir2 blocks extreme life-span extension. Cell 2005, 123:655-667.
64. + in SK-N-SH cells. FEBS Lett. 2006, 580:3091-3098.
65. Ferrington D.A., Gregerson D.S. Immunoproteasomes: structure, function, and antigen presentation. Progr. Mol. Biol. Transl. Sci. 2012, 109:75-112.
66. Fitzgerald P., Mandel A., Bolton A.E., Sullivan A.M., Nolan Y. Treatment with phosphotidylglycerol-based nanoparticles prevents motor deficits induced by proteasome inhibition: implications for Parkinson's disease. Behav. Brain Res. 2008, 195:271-274.
67. Fontana L., Partridge L., Longo V.D. Extending healthy life span - from yeast to humans. Science (New York, NY) 2010, 328:321-326.
68. Fredriksson A., Johansson Krogh E., Hernebring M., Pettersson E., Javadi A., Almstedt A., Nystrom T. Effects of aging and reproduction on protein quality control in soma and gametes of Drosophila melanogaster. Aging Cell 2012, 11:634-643.
69. Fu R.H., Harn H.J., Liu S.P., Chen C.S., Chang W.L., Chen Y.M., Huang J.E., Li R.J., Tsai S.Y., Hung H.S., Shyu W.C., Lin S.Z., Wang Y.C. n-Butylidenephthalide protects against dopaminergic neuron degeneration and alpha-synuclein accumulation in Caenorhabditis elegans models of Parkinson's disease. PLOS ONE 2014, 9:e85305.
70. Fu R.H., Wang Y.C., Chen C.S., Tsai R.T., Liu S.P., Chang W.L., Lin H.L., Lu C.H., Wei J.R., Wang Z.W., Shyu W.C., Lin S.Z. Acetylcorynoline attenuates dopaminergic neuron degeneration and alpha-synuclein aggregation in animal models of Parkinson's disease. Neuropharmacology 2014, 82:108-120.
71. Gaczynska M., Goldberg A.L., Tanaka K., Hendil K.B., Rock K.L. Proteasome subunits X and Y alter peptidase activities in opposite ways to the interferon-gamma-induced subunits LMP2 and LMP7. J. Biol. Chem. 1996, 271:17275-17280.
72. Gaczynska M., Rock K.L., Spies T., Goldberg A.L. Peptidase activities of proteasomes are differentially regulated by the major histocompatibility complex-encoded genes for LMP2 and LMP7. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:9213-9217.
73. Galanty Y., Belotserkovskaya R., Coates J., Polo S., Miller K.M., Jackson S.P. Mammalian SUMO E3-ligases PIAS1 and PIAS4 promote responses to DNA double-strand breaks. Nature 2009, 462:935-939.
74. Gan N., Wu Y.C., Brunet M., Garrido C., Chung F.L., Dai C., Mi L. Sulforaphane activates heat shock response and enhances proteasome activity through up-regulation of Hsp27. J. Biol. Chem. 2010, 285:35528-35536.
75. Gavilan M.P., Castano A., Torres M., Portavella M., Caballero C., Jimenez S., Garcia-Martinez A., Parrado J., Vitorica J., Ruano D. Age-related increase in the immunoproteasome content in rat hippocampus: molecular and functional aspects. J. Neurochem. 2009, 108:260-272.
76. Ghazi A., Henis-Korenblit S., Kenyon C. Regulation of Caenorhabditis elegans lifespan by a proteasomal E3 ligase complex. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:5947-5952.
77. Goldberg A.L. Functions of the proteasome: from protein degradation and immune surveillance to cancer therapy. Biochem. Soc. Trans. 2007, 35:12-17.
78. Goto S., Takahashi R., Radak Z., Sharma R. Beneficial biochemical outcomes of late-onset dietary restriction in rodents. Ann. N. Y. Acad. Sci. 2007, 1100:431-441.
79. Graikou K., Kapeta S., Aligiannis N., Sotiroudis G., Chondrogianni N., Gonos E., Chinou I. Chemical analysis of Greek pollen - antioxidant, antimicrobial and proteasome activation properties. Chem. Cent. J. 2011, 5:33.
80. Groettrup M., Kirk C.J., Basler M. Proteasomes in immune cells: more than peptide producers?. Nat. Rev. Immunol. 2010, 10:73-78.
81. Groll M., Bochtler M., Brandstetter H., Clausen T., Huber R. Molecular machines for protein degradation. Chembiochem 2005, 6:222-256.
82. Guillaume B., Stroobant V., Bousquet-Dubouch M.P., Colau D., Chapiro J., Parmentier N., Dalet A., Van den Eynde B.J. Analysis of the processing of seven human tumor antigens by intermediate proteasomes. J. Immunol. 2012, 189:3538-3547.
83. Hamamichi S., Rivas R.N., Knight A.L., Cao S., Caldwell K.A., Caldwell G.A. Hypothesis-based RNAi screening identifies neuroprotective genes in a Parkinson's disease model. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:728-733.
84. Hassan W.M., Merin D.A., Fonte V., Link C.D. AIP-1 ameliorates beta-amyloid peptide toxicity in a Caenorhabditis elegans Alzheimer's disease model. Hum. Mol. Genet. 2009, 18:2739-2747.
85. He P., Zhong Z., Lindholm K., Berning L., Lee W., Lemere C., Staufenbiel M., Li R., Shen Y. Deletion of tumor necrosis factor death receptor inhibits amyloid beta generation and prevents learning and memory deficits in Alzheimer's mice. J. Cell Biol. 2007, 178:829-841.
86. Henkel J.S., Beers D.R., Siklos L., Appel S.H. The chemokine MCP-1 and the dendritic and myeloid cells it attracts are increased in the mSOD1 mouse model of ALS. Mol. Cell. Neurosci. 2006, 31:427-437.
87. Henkel J.S., Engelhardt J.I., Siklos L., Simpson E.P., Kim S.H., Pan T., Goodman J.C., Siddique T., Beers D.R., Appel S.H. Presence of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue. Ann. Neurol. 2004, 55:221-235.
88. Himeno E., Ohyagi Y., Ma L., Nakamura N., Miyoshi K., Sakae N., Motomura K., Soejima N., Yamasaki R., Hashimoto T., Tabira T., LaFerla F.M., Kira J. Apomorphine treatment in Alzheimer mice promoting amyloid-beta degradation. Ann. Neurol. 2011, 69:248-256.
89. Hipp M.S., Patel C.N., Bersuker K., Riley B.E., Kaiser S.E., Shaler T.A., Brandeis M., Kopito R.R. Indirect inhibition of 26S proteasome activity in a cellular model of Huntington's disease. J. Cell Biol. 2012, 196:573-587.
90. Hoglinger G.U., Carrard G., Michel P.P., Medja F., Lombes A., Ruberg M., Friguet B., Hirsch E.C. Dysfunction of mitochondrial complex I and the proteasome: interactions between two biochemical deficits in a cellular model of Parkinson's disease. J. Neurochem. 2003, 86:1297-1307.
91. Hunter J.M., Lesort M., Johnson G.V. Ubiquitin-proteasome system alterations in a striatal cell model of Huntington's disease. J. Neurosci. Res. 2007, 85:1774-1788.
92. Hwang J.S., Hwang J.S., Chang I., Kim S. Age-associated decrease in proteasome content and activities in human dermal fibroblasts: restoration of normal level of proteasome subunits reduces aging markers in fibroblasts from elderly persons. J. Gerontol. A: Biol. Sci. Med. Sci. 2007, 62:490-499.
93. Hyun D.H., Lee M., Hattori N., Kubo S., Mizuno Y., Halliwell B., Jenner P. Effect of wild-type or mutant Parkin on oxidative damage, nitric oxide, antioxidant defenses, and the proteasome. J. Biol. Chem. 2002, 277:28572-28577.
94. Indig F.E., Partridge J.J., von Kobbe C., Aladjem M.I., Latterich M., Bohr V.A. Werner syndrome protein directly binds to the AAA ATPase p97/VCP in an ATP-dependent fashion. J. Struct. Biol. 2004, 146:251-259.
95. Jana N.R., Dikshit P., Goswami A., Kotliarova S., Murata S., Tanaka K., Nukina N. Co-chaperone CHIP associates with expanded polyglutamine protein and promotes their degradation by proteasomes. J. Biol. Chem. 2005, 280:11635-11640.
96. Jana N.R., Zemskov E.A., Wang G.-H., Nukina N. Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. Hum. Mol. Genet. 2001, 10:1049-1059.
97. Jang J., Wang Y., Kim H.S., Lalli M.A., Kosik K.S. Nrf2, a regulator of the proteasome, controls self-renewal and pluripotency in human embryonic stem cells. Stem Cells 2014, 32:2616-2625.
98. Jenner P., Olanow C.W. Understanding cell death in Parkinson's disease. Ann. Neurol. 1998, 44:S72-S84.
99. Jia H., Kast R.J., Steffan J.S., Thomas E.A. Selective histone deacetylase (HDAC) inhibition imparts beneficial effects in Huntington's disease mice: implications for the ubiquitin-proteasomal and autophagy systems. Hum. Mol. Genet. 2012, 21:5280-5293.
100. Ju D., Wang X., Xu H., Xie Y. Genome-wide analysis identifies MYND-domain protein Mub1 as an essential factor for Rpn4 ubiquitylation. Mol. Cell. Biol. 2008, 28:1404-1412.
101. Ju D., Xu H., Wang X., Xie Y. Ubiquitin-mediated degradation of Rpn4 is controlled by a phosphorylation-dependent ubiquitylation signal. Biochim. Biophys. Acta 2007, 1773:1672-1680.
102. Kabashi E., Agar J.N., Hong Y., Taylor D.M., Minotti S., Figlewicz D.A., Durham H.D. Proteasomes remain intact, but show early focal alteration in their composition in a mouse model of amyotrophic lateral sclerosis. J. Neurochem. 2008, 105:2353-2366.
103. Kabashi E., Agar J.N., Strong M.J., Durham H.D. Impaired proteasome function in sporadic amyotrophic lateral sclerosis. Amyotroph. Later. Scler.: Off. Publ. World Fed. Neurol. Res. Group Motor Neuron Dis. 2012, 13:367-371.
104. Kahn Nate W., Rea Shane L., Moyle S., Kell A., Johnson Thomas E. Proteasomal dysfunction activates the transcription factor SKN-1 and produces a selective oxidative-stress response in Caenorhabditis elegans. Biochem. J. 2008, 409:205.
105. Kahyo T., Mostoslavsky R., Goto M., Setou M. Sirtuin-mediated deacetylation pathway stabilizes Werner syndrome protein. FEBS Lett. 2008, 582:2479-2483.
106. Kaneko M., Okuma Y., Nomura Y. Molecular approaches to the treatment, prophylaxis, and diagnosis of Alzheimer's disease: possible involvement of HRD1, a novel molecule related to endoplasmic reticulum stress, in Alzheimer's disease. J. Pharmacol. Sci. 2012, 118:325-330.
107. Kapeta S., Chondrogianni N., Gonos E.S. Nuclear erythroid factor 2-mediated proteasome activation delays senescence in human fibroblasts. J. Biol. Chem. 2010, 285:8171-8184.
108. Karras G.I., Jentsch S. The RAD6 DNA damage tolerance pathway operates uncoupled from the replication fork and is functional beyond S phase. Cell 2010, 141:255-267.
109. Kato S. Amyotrophic lateral sclerosis models and human neuropathology: similarities and differences. Acta Neuropathol. (Berl.) 2008, 115:97-114.
110. Katsiki M., Chondrogianni N., Chinou I., Rivett A.J., Gonos E.S. The olive constituent oleuropein exhibits proteasome stimulatory properties in vitro and confers life span extension of human embryonic fibroblasts. Rejuv. Res. 2007, 10:157-172.
111. Keck S., Nitsch R., Grune T., Ullrich O. Proteasome inhibition by paired helical filament-tau in brains of patients with Alzheimer's disease. J. Neurochem. 2003, 85:115-122.
112. Keller J.N., Hanni K.B., Markesbery W.R. Impaired proteasome function in Alzheimer's disease. J. Neurochem. 2000, 75:436-439.
113. Kenyon C. The plasticity of aging: insights from long-lived mutants. Cell 2005, 120:449-460.
114. Kim H., D'Andrea A.D. Regulation of DNA cross-link repair by the Fanconi anemia/BRCA pathway. Genes Dev. 2012, 26:1393-1408.
115. Kim S.H., Jung S.Y., Lee K.W., Lee S.H., Cai M., Choi S.M., Yang E.J. Bee venom effects on ubiquitin proteasome system in hSOD1(G85R)-expressing NSC34 motor neuron cells. BMC Complement. Altern. Med. 2013, 13:179.
116. Kish-Trier E., Hill C.P. Structural biology of the proteasome. Ann. Rev. Biophys. 2013, 42:29-49.
117. Knipscheer P., Raschle M., Smogorzewska A., Enoiu M., Ho T.V., Scharer O.D., Elledge S.J., Walter J.C. The Fanconi anemia pathway promotes replication-dependent DNA interstrand cross-link repair. Science 2009, 326:1698-1701.
118. Kolas N.K., Chapman J.R., Nakada S., Ylanko J., Chahwan R., Sweeney F.D., Panier S., Mendez M., Wildenhain J., Thomson T.M., Pelletier L., Jackson S.P., Durocher D. Orchestration of the DNA-damage response by the RNF8 ubiquitin ligase. Science 2007, 318:1637-1640.
119. Koulich E., Li X., DeMartino G.N. Relative structural and functional roles of multiple deubiquitylating proteins associated with mammalian 26S proteasome. Mol. Biol. Cell 2008, 19:1072-1082.
120. Kruegel U., Robison B., Dange T., Kahlert G., Delaney J.R., Kotireddy S., Tsuchiya M., Tsuchiyama S., Murakami C.J., Schleit J., Sutphin G., Carr D., Tar K., Dittmar G., Kaeberlein M., Kennedy B.K., Schmidt M. Elevated proteasome capacity extends replicative lifespan in Saccharomyces cerevisiae. PLoS Genet. 2011, 7:e1002253.
121. Kumar P., Ambasta R.K., Veereshwarayya V., Rosen K.M., Kosik K.S., Band H., Mestril R., Patterson C., Querfurth H.W. CHIP and HSPs interact with beta-APP in a proteasome-dependent manner and influence Abeta metabolism. Hum. Mol. Genet. 2007, 16:848-864.
122. Kwak M.K., Cho J.M., Huang B., Shin S., Kensler T.W. Role of increased expression of the proteasome in the protective effects of sulforaphane against hydrogen peroxide-mediated cytotoxicity in murine neuroblastoma cells. Free Radic. Biol. Med. 2007, 43:809-817.
123. Kwak M.K., Wakabayashi N., Greenlaw J.L., Yamamoto M., Kensler T.W. Antioxidants enhance mammalian proteasome expression through the Keap1-Nrf2 signaling pathway. Mol. Cell. Biol. 2003, 23:8786-8794.
124. Kyng K.J., May A., Stevnsner T., Becker K.G., Kolvra S., Bohr V.A. Gene expression responses to DNA damage are altered in human aging and in Werner Syndrome. Oncogene 2005, 24:5026-5042.
125. Laporte D., Salin B., Daignan-Fornier B., Sagot I. Reversible cytoplasmic localization of the proteasome in quiescent yeast cells. J. Cell Biol. 2008, 181:737-745.
126. Larizza L., Magnani I., Roversi G. Rothmund-Thomson syndrome and RECQL4 defect: splitting and lumping. Cancer Lett. 2006, 232:107-120.
127. Le W., Sayana P., Jankovic J. Animal models of Parkinson's disease: a gateway to therapeutics?. Neurotherap.: J. Am. Soc. Exp. NeuroTherap. 2014, 11:92-110.
128. Lee B.H., Lee M.J., Park S., Oh D.C., Elsasser S., Chen P.C., Gartner C., Dimova N., Hanna J., Gygi S.P., Wilson S.M., King R.W., Finley D. Enhancement of proteasome activity by a small-molecule inhibitor of USP14. Nature 2010, 467:179-184.
129. Lee F.K., Wong A.K., Lee Y.W., Wan O.W., Chan H.Y., Chung K.K. The role of ubiquitin linkages on alpha-synuclein induced-toxicity in a Drosophila model of Parkinson's disease. J. Neurochem. 2009, 110:208-219.
130. Lee S.S., Kennedy S., Tolonen A.C., Ruvkun G. DAF-16 target genes that control C. elegans life-span and metabolism. Science 2003, 300:644-647.
131. Leung C.K., Hasegawa K., Wang Y., Deonarine A., Tang L., Miwa J., Choe K.P. Direct interaction between the WD40 repeat protein WDR-23 and SKN-1/Nrf inhibits binding to target DNA. Mol. Cell. Biol. 2014, 34:3156-3167.
132. Li C., Biswas S., Li X., Dutta A.K., Le W. Novel D3 dopamine receptor-preferring agonist D-264: evidence of neuroprotective property in Parkinson's disease animal models induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and lactacystin. J. Neurosci. Res. 2010, 88:2513-2523.
133. Li C., Guo Y., Xie W., Li X., Janokovic J., Le W. Neuroprotection of pramipexole in UPS impairment induced animal model of Parkinson's disease. Neurochem. Res. 2010, 35:1546-1556.
134. Li J., Horak K.M., Su H., Sanbe A., Robbins J., Wang X. Enhancement of proteasomal function protects against cardiac proteinopathy and ischemia/reperfusion injury in mice. J. Clin. Invest. 2011, 121:3689-3700.
135. Li W., Gao B., Lee S.M., Bennett K., Fang D. RLE-1, an E3 ubiquitin ligase, regulates C. elegans aging by catalyzing DAF-16 polyubiquitination. Dev. Cell 2007, 12:235-246.
136. Li X., Matilainen O., Jin C., Glover-Cutter K.M., Holmberg C.I., Blackwell T.K. Specific SKN-1/Nrf stress responses to perturbations in translation elongation and proteasome activity. PLoS Genet. 2011, 7:e1002119.
137. Li X., Wang C.E., Huang S., Xu X., Li X.J., Li H., Li S. Inhibiting the ubiquitin-proteasome system leads to preferential accumulation of toxic N-terminal mutant huntingtin fragments. Hum. Mol. Genet. 2010, 19:2445-2455.
138. Lin K., Dorman J.B., Rodan A., Kenyon C. daf-16: an HNF-3/forkhead Family Member that can function to double the life span of Caenorhabditis elegans. Science 1997, 278:1319-1322.
139. Lindsten K., de Vrij F.M., Verhoef L.G., Fischer D.F., van Leeuwen F.W., Hol E.M., Masucci M.G., Dantuma N.P. Mutant ubiquitin found in neurodegenerative disorders is a ubiquitin fusion degradation substrate that blocks proteasomal degradation. J. Cell Biol. 2002, 157:417-427.
140. Link C.D., Taft A., Kapulkin V., Duke K., Kim S., Fei Q., Wood D.E., Sahagan B.G. Gene expression analysis in a transgenic Caenorhabditis elegans Alzheimer's disease model. Neurobiol. Aging 2003, 24:397-413.
141. Liu G., Rogers J., Murphy C.T., Rongo C. EGF signalling activates the ubiquitin proteasome system to modulate C. elegans lifespan. EMBO J. 2011, 30:2990-3003.
142. Liu Y., Hettinger C.L., Zhang D., Rezvani K., Wang X., Wang H. Sulforaphane enhances proteasomal and autophagic activities in mice and is a potential therapeutic reagent for Huntington's disease. J. Neurochem. 2014, 129:539-547.
143. Liu Y., Liu X., Zhang T., Luna C., Liton P.B., Gonzalez P. Cytoprotective effects of proteasome beta5 subunit overexpression in lens epithelial cells. Mol. Vis. 2007, 13:31-38.
144. Lonskaya I., Desforges N.M., Hebron M.L., Moussa C.E. Ubiquitination increases parkin activity to promote autophagic alpha-synuclein clearance. PLoS ONE 2013, 8:e83914.
145. Lopez-Otin C., Blasco M.A., Partridge L., Serrano M., Kroemer G. The hallmarks of aging. Cell 2013, 153:1194-1217.
146. Lopez Salon M., Morelli L., Castano E.M., Soto E.F., Pasquini J.M. Defective ubiquitination of cerebral proteins in Alzheimer's disease. J. Neurosci. Res. 2000, 62:302-310.
147. Lu B., Al-Ramahi I., Valencia A., Wang Q., Berenshteyn F., Yang H., Gallego-Flores T., Ichcho S., Lacoste A., Hild M., Difiglia M., Botas J., Palacino J. Identification of NUB1 as a suppressor of mutant Huntington toxicity via enhanced protein clearance. Nat. Neurosci. 2013, 16:562-570.
148. Lu L., Song H.F., Wei J.L., Liu X.Q., Song W.H., Yan B.Y., Yang G.J., Li A., Yang W.L. Ameliorating replicative senescence of human bone marrow stromal cells by PSMB5 overexpression. Biochem. Biophys. Res. Commun. 2014, 443:1182-1188.
149. Luchsinger J.A., Tang M.-X., Siddiqui M., Shea S., Mayeux R. Alcohol intake and risk of dementia. J. Am. Geriatr. Soc. 2004, 52:540-546.
150. Luijsterburg M.S., van Attikum H. Close encounters of the RNF8th kind: when chromatin meets DNA repair. Curr. Opin. Cell Biol. 2012, 24:439-447.
151. MacDonald M.E., Ambrose C.M., Duyao M.P., Myers R.H., Lin C., Srinidhi L., Barnes G., Taylor S.A., James M., Groot N., MacFarlane H., Jenkins B., Anderson M.A., Wexler N.S., Gusella J.F., Bates G.P., Baxendale S., Hummerich H., Kirby S., North M., Youngman S., Mott R., Zehetner G., Sedlacek Z., Poustka A., Frischauf A.-M., Lehrach H., Buckler A.J., Church D., Doucette-Stamm L., O'Donovan M.C., Riba-Ramirez L., Shah M., Stanton V.P., Strobel S.A., Draths K.M., Wales J.L., Dervan P., Housman D.E., Altherr M., Shiang R., Thompson L., Fielder T., Wasmuth J.J., Tagle D., Valdes J., Elmer L., Allard M., Castilla L., Swaroop M., Blanchard K., Collins F.S., Snell R., Holloway T., Gillespie K., Datson N., Shaw D., Harper P.S. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993, 72:971-983.
152. Malhotra D., Thimmulappa R., Vij N., Navas-Acien A., Sussan T., Merali S., Zhang L., Kelsen S.G., Myers A., Wise R., Tuder R., Biswal S. Heightened endoplasmic reticulum stress in the lungs of patients with chronic obstructive pulmonary disease: the role of Nrf2-regulated proteasomal activity. Am. J. Respir. Crit. Care Med. 2009, 180:1196-1207.
153. Mannhaupt G., Schnall R., Karpov V., Vetter I., Feldmann H. Rpn4p acts as a transcription factor by binding to PACE, a nonamer box found upstream of 26S proteasomal and other genes in yeast. FEBS Lett. 1999, 450:27-34.
154. Marambaud P., Zhao H., Davies P. Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides. J. Biol. Chem. 2005, 280:37377-37382.
155. Marino M., Papa S., Crippa V., Nardo G., Peviani M., Cheroni C., Trolese M.C., Lauranzano E., Bonetto V., Poletti A., DeBiasi S., Ferraiuolo L., Shaw P.J., Bendotti C. Differences in protein quality control correlate with phenotype variability in 2 mouse models of familial amyotrophic lateral sclerosis. Neurobiol. Aging 2015, 36:492-504.
156. Martin G.M. Genetic syndromes in man with potential relevance to the pathobiology of aging. Birth Defects Orig. Artic. Ser. 1978, 14:5-39.
157. Martin G.M. Genetic modulation of senescent phenotypes in Homo sapiens. Cell 2005, 120:523-532.
158. Matilainen O., Arpalahti L., Rantanen V., Hautaniemi S., Holmberg C.I. Insulin/IGF-1 signaling regulates proteasome activity through the deubiquitinating enzyme UBH-4. Cell Rep. 2013, 3:1980-1995.
159. McCutchen-Maloney S.L., Matsuda K., Shimbara N., Binns D.D., Tanaka K., Slaughter C.A., DeMartino G.N. cDNA cloning, expression, and functional characterization of PI31, a proline-rich inhibitor of the proteasome. J. Biol. Chem. 2000, 275:18557-18565.
160. McNaught K.S., Belizaire R., Isacson O., Jenner P., Olanow C.W. Altered proteasomal function in sporadic Parkinson's disease. Exp. Neurol. 2003, 179:38-46.
161. McNaught K.S., Bjorklund L.M., Belizaire R., Isacson O., Jenner P., Olanow C.W. Proteasome inhibition causes nigral degeneration with inclusion bodies in rats. Neuroreport 2002, 13:1437-1441.
162. McNaught K.S., Jenner P. Proteasomal function is impaired in substantia nigra in Parkinson's disease. Neurosci. Lett. 2001, 297:191-194.
163. McNaught K.S., Jnobaptiste R., Jackson T., Jengelley T.A. The pattern of neuronal loss and survival may reflect differential expression of proteasome activators in Parkinson's disease. Synapse 2010, 64:241-250.
164. McNaught K.S., Perl D.P., Brownell A.L., Olanow C.W. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann. Neurol. 2004, 56:149-162.
165. Medina D.X., Caccamo A., Oddo S. Methylene blue reduces abeta levels and rescues early cognitive deficit by increasing proteasome activity. Brain Pathol. 2011, 21:140-149.
166. Mehta R., Steinkraus K.A., Sutphin G.L., Ramos F.J., Shamieh L.S., Huh A., Davis C., Chandler-Brown D., Kaeberlein M. Proteasomal regulation of the hypoxic response modulates aging in C. elegans. Science 2009, 324:1196-1198.
167. Meyer H., Bug M., Bremer S. Emerging functions of the VCP/p97 AAA-ATPase in the ubiquitin system. Nat. Cell Biol. 2012, 14:117-123.
168. Minelli A., Conte C., Prudenzi E., Cacciatore I., Cornacchia C., Taha E., Pinnen F. N-acetyl-l-methionyl-l-Dopa-methyl ester as a dual acting drug that relieves l-Dopa-induced oxidative toxicity. Free Radic. Biol. Med. 2010, 49:31-39.
169. Mishto M., Bellavista E., Santoro A., Stolzing A., Ligorio C., Nacmias B., Spazzafumo L., Chiappelli M., Licastro F., Sorbi S., Pession A., Ohm T., Grune T., Franceschi C. Immunoproteasome and LMP2 polymorphism in aged and Alzheimer's disease brains. Neurobiol. Aging 2006, 27:54-66.
170. Mori A., Yamashita S., Uchino K., Suga T., Ikeda T., Takamatsu K., Ishizaki M., Koide T., Kimura E., Mita S., Maeda Y., Hirano T., Uchino M. Derlin-1 overexpression ameliorates mutant SOD1-induced endoplasmic reticulum stress by reducing mutant SOD1 accumulation. Neurochem. Int. 2011, 58:344-353.
171. Moskalev A., Shaposhnikov M., Turysheva E. Life span alteration after irradiation in Drosophila melanogaster strains with mutations of Hsf and Hsps. Biogerontology 2009, 10:3-11.
172. Moskalev A.A., Pliusnina E.N., Zainullin V.G. The influence of low doze gamma-irradiation on life span of Drosophila mutants with defects of DNA damage sensation and repair. Radiatsionnaia biologiia, radioecologiia/Rossiiskaia akademiia nauk 2007, 47:571-573.
173. Murphy C.T., McCarroll S.A., Bargmann C.I., Fraser A., Kamath R.S., Ahringer J., Li H., Kenyon C. Genes that act downstream of DAF-16 to influence the lifespan of Caenorhabditis elegans. Nature 2003, 424:277-283.
174. Naoi M., Maruyama W., Yi H., Akao Y., Yamaoka Y., Shamoto-Nagai M. Neuroprotection by propargylamines in Parkinson's disease: intracellular mechanism underlying the anti-apoptotic function and search for clinical markers. J. Neural Transm. Suppl. 2007, 121-131.
175. Navarro C.L., Cau P., Levy N. Molecular bases of progeroid syndromes. Hum. Mol. Genet. 2006, 15(Spec. No. 2):R151-R161.
176. Neymotin A., Calingasan N.Y., Wille E., Naseri N., Petri S., Damiano M., Liby K.T., Risingsong R., Sporn M., Beal M.F., Kiaei M. Neuroprotective effect of Nrf2/ARE activators, CDDO ethylamide and CDDO trifluoroethylamide, in a mouse model of amyotrophic lateral sclerosis. Free Radic. Biol. Med. 2011, 51:88-96.
177. Nguyen T., Yang C.S., Pickett C.B. The pathways and molecular mechanisms regulating Nrf2 activation in response to chemical stress. Free Radic. Biol. Med. 2004, 37:433-441.
178. Nickell S., Beck F., Scheres S.H., Korinek A., Forster F., Lasker K., Mihalache O., Sun N., Nagy I., Sali A., Plitzko J.M., Carazo J.M., Mann M., Baumeister W. Insights into the molecular architecture of the 26S proteasome. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:11943-11947.
179. Nijholt D.A., de Graaf T.R., van Haastert E.S., Oliveira A.O., Berkers C.R., Zwart R., Ovaa H., Baas F., Hoozemans J.J., Scheper W. Endoplasmic reticulum stress activates autophagy but not the proteasome in neuronal cells: implications for Alzheimer's disease. Cell Death Differ. 2011, 18:1071-1081.
180. Oddo S. The ubiquitin-proteasome system in Alzheimer's disease. J. Cell. Mol. Med. 2008, 12:363-373.
181. Ohnishi K., Nakahata E., Irie K., Murakami A. Zerumbone, an electrophilic sesquiterpene, induces cellular proteo-stress leading to activation of ubiquitin-proteasome system and autophagy. Biochem. Biophys. Res. Commun. 2013, 430:616-622.
182. Oling D., Eisele F., Kvint K., Nystrom T. Opposing roles of Ubp3-dependent deubiquitination regulate replicative life span and heat resistance. EMBO J. 2014, 33:747-761.
183. Opattova A., Filipcik P., Cente M., Novak M. Intracellular degradation of misfolded tau protein induced by geldanamycin is associated with activation of proteasome. J. Alzheimer's Dis.: JAD 2013, 33:339-348.
184. Orr A.L., Li S., Wang C.E., Li H., Wang J., Rong J., Xu X., Mastroberardino P.G., Greenamyre J.T., Li X.J. N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking. J. Neurosci.: Off. J. Soc. Neurosci. 2008, 28:2783-2792.
185. Orre M., Kamphuis W., Dooves S., Kooijman L., Chan E.T., Kirk C.J., Dimayuga Smith V., Koot S., Mamber C., Jansen A.H., Ovaa H., Hol E.M. Reactive glia show increased immunoproteasome activity in Alzheimer's disease. Brain 2013, 136:1415-1431.
186. Pehar M., Vargas M.R., Robinson K.M., Cassina P., Diaz-Amarilla P.J., Hagen T.M., Radi R., Barbeito L., Beckman J.S. Mitochondrial superoxide production and nuclear factor erythroid 2-related factor 2 activation in p75 neurotrophin receptor-induced motor neuron apoptosis. J. Neurosci.: Off. J. Soc. Neurosci. 2007, 27:7777-7785.
187. Perez V.I., Buffenstein R., Masamsetti V., Leonard S., Salmon A.B., Mele J., Andziak B., Yang T., Edrey Y., Friguet B., Ward W., Richardson A., Chaudhuri A. Protein stability and resistance to oxidative stress are determinants of longevity in the longest-living rodent, the naked mole-rat. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:3059-3064.
188. Perry G., Friedman R., Shaw G., Chau V. Ubiquitin is detected in neurofibrillary tangles and senile plaque neurites of Alzheimer disease brains. Proc. Natl. Acad. Sci. U. S. A. 1987, 84:3033-3036.
189. Petropoulos I., Conconi M., Wang X., Hoenel B., Bregegere F., Milner Y., Friguet B. Increase of oxidatively modified protein is associated with a decrease of proteasome activity and content in aging epidermal cells. J. Gerontol. A: Biol. Sci. Med. Sci. 2000, 55:B220-B227.
190. Pickering A.M., Koop A.L., Teoh C.Y., Ermak G., Grune T., Davies K.J. The immunoproteasome, the 20S proteasome and the PA28alphabeta proteasome regulator are oxidative-stress-adaptive proteolytic complexes. Biochem. J. 2010, 432:585-594.
191. Pickering A.M., Staab T.A., Tower J., Sieburth D., Davies K.J. A conserved role for the 20S proteasome and Nrf2 transcription factor in oxidative stress adaptation in mammals, Caenorhabditis elegans and Drosophila melanogaster. J. Exp. Biol. 2013, 216:543-553.
192. Ponnappan U., Zhong M., Trebilcock G.U. Decreased proteasome-mediated degradation in T cells from the elderly: a role in immune senescence. Cell. Immunol. 1999, 192:167-174.
193. Przybysz A.J., Choe K.P., Roberts L.J., Strange K. Increased age reduces DAF-16 and SKN-1 signaling and the hormetic response of Caenorhabditis elegans to the xenobiotic juglone. Mech. Ageing Dev. 2009, 130:357-369.
194. Rana A., Rera M., Walker D.W. Parkin overexpression during aging reduces proteotoxicity, alters mitochondrial dynamics, and extends lifespan. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:8638-8643.
195. Ranek M.J., Terpstra E.J., Li J., Kass D.A., Wang X. Protein kinase g positively regulates proteasome-mediated degradation of misfolded proteins. Circulation 2013, 128:365-376.
196. Rechsteiner M., Hill C.P. Mobilizing the proteolytic machine: cell biological roles of proteasome activators and inhibitors. Trends Cell Biol. 2005, 15:27-33.
197. Regitz C., Marie Dussling L., Wenzel U. Amyloid-beta (Abeta1-42)-induced paralysis in Caenorhabditis elegans is inhibited by the polyphenol quercetin through activation of protein degradation pathways. Mol. Nutr. Food Res. 2014, 58:1931-1940.
198. Riederer B.M., Leuba G., Vernay A., Riederer I.M. The role of the ubiquitin proteasome system in Alzheimer's disease. Exp. Biol. Med. (Maywood, NJ) 2011, 236:268-276.
199. Rodriguez K.A., Edrey Y.H., Osmulski P., Gaczynska M., Buffenstein R. Altered composition of liver proteasome assemblies contributes to enhanced proteasome activity in the exceptionally long-lived naked mole-rat. PLoS ONE 2012, 7:e35890.
200. Rodriguez K.A., Osmulski P.A., Pierce A., Weintraub S.T., Gaczynska M., Buffenstein R. A cytosolic protein factor from the naked mole-rat activates proteasomes of other species and protects these from inhibition. Biochim. Biophys. Acta (BBA) - Mol. Basis Dis. 2014, 1842:2060-2072.
201. Saez I., Vilchez D. The mechanistic links between proteasome activity, aging and age-related diseases. Curr. Genomics 2014, 15:38-51.
202. Safren N., El Ayadi A., Chang L., Terrillion C.E., Gould T.D., Boehning D.F., Monteiro M.J. Ubiquilin-1 overexpression increases the lifespan and delays accumulation of Huntingtin aggregates in the R6/2 mouse model of Huntington's disease. PLOS ONE 2014, 9:e87513.
203. Sarlette A., Krampfl K., Grothe C., Neuhoff N., Dengler R., Petri S. Nuclear erythroid 2-related factor 2-antioxidative response element signaling pathway in motor cortex and spinal cord in amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 2008, 67:1055-1062.
204. Saunier R., Esposito M., Dassa E.P., Delahodde A. Integrity of the Saccharomyces cerevisiae Rpn11 protein is critical for formation of proteasome storage granules (PSG) and survival in stationary phase. PLoS ONE 2013, 8:e70357.
205. Schipper-Krom S., Juenemann K., Jansen A.H., Wiemhoefer A., van den Nieuwendijk R., Smith D.L., Hink M.A., Bates G.P., Overkleeft H., Ovaa H., Reits E. Dynamic recruitment of active proteasomes into polyglutamine initiated inclusion bodies. FEBS Lett. 2014, 588:151-159.
206. Schumacher B., Garinis G.A., Hoeijmakers J.H. Age to survive: DNA damage and aging. Trends Genet. 2008, 24:77-85.
207. Seo H., Sonntag K.C., Isacson O. Generalized brain and skin proteasome inhibition in Huntington's disease. Ann. Neurol. 2004, 56:319-328.
208. Seo H., Sonntag K.C., Kim W., Cattaneo E., Isacson O. Proteasome activator enhances survival of Huntington's disease neuronal model cells. PLoS ONE 2007, 2:e238.
209. Sieradzan K.A., Mechan A.O., Jones L., Wanker E.E., Nukina N., Mann D.M. Huntington's disease intranuclear inclusions contain truncated, ubiquitinated huntingtin protein. Exp. Neurol. 1999, 156:92-99.
210. Smogorzewska A., Matsuoka S., Vinciguerra P., McDonald E.R., Hurov K.E., Luo J., Ballif B.A., Gygi S.P., Hofmann K., D'Andrea A.D., Elledge S.J. Identification of the FANCI protein, a monoubiquitinated FANCD2 paralog required for DNA repair. Cell 2007, 129:289-301.
211. Soares J.P., Cortinhas A., Bento T., Leitao J.C., Collins A.R., Gaivao I., Mota M.P. Aging and DNA damage in humans: a meta-analysis study. Aging (Albany, NY) 2014, 6:432-439.
212. Sok J., Calfon M., Lu J., Lichtlen P., Clark S.G., Ron D. Arsenite-inducible RNA-associated protein (AIRAP) protects cells from arsenite toxicity. Cell Stress Chaper. 2001, 6:6-15.
213. Sone J., Niwa J., Kawai K., Ishigaki S., Yamada S., Adachi H., Katsuno M., Tanaka F., Doyu M., Sobue G. Dorfin ameliorates phenotypes in a transgenic mouse model of amyotrophic lateral sclerosis. J. Neurosci. Res. 2010, 88:123-135.
214. Spatola M., Wider C. Genetics of Parkinson's disease: the yield. Parkinson. Relat. Disord. 2014, 20(Suppl. 1):S35L 38.
215. Stanhill A., Haynes C.M., Zhang Y., Min G., Steele M.C., Kalinina J., Martinez E., Pickart C.M., Kong X.P., Ron D. An arsenite-inducible 19S regulatory particle-associated protein adapts proteasomes to proteotoxicity. Mol. Cell 2006, 23:875-885.
216. Stark M., Behl C. The ginkgo biloba extract EGb 761 modulates proteasome activity and polyglutamine protein aggregation. Evid.-Based Complement. Altern. Med.: eCAM 2014, 2014:940186.
217. Starke S., Meinke P., Camozzi D., Mattioli E., Pfaeffle R., Siekmeyer M., Hirsch W., Horn L.C., Paasch U., Mitter D., Lattanzi G., Wehnert M., Kiess W. Progeroid laminopathy with restrictive dermopathy-like features caused by an isodisomic LMNA mutation p.R435C. Aging (Albany, NY) 2013, 5:445-459.
218. Stewart C.L., Kozlov S., Fong L.G., Young S.G. Mouse models of the laminopathies. Exp. Cell Res. 2007, 313:2144-2156.
219. Stout G.J., Stigter E.C., Essers P.B., Mulder K.W., Kolkman A., Snijders D.S., van den Broek N.J., Betist M.C., Korswagen H.C., Macinnes A.W., Brenkman A.B. Insulin/IGF-1-mediated longevity is marked by reduced protein metabolism. Mol. Syst. Biol. 2013, 9:679.
220. Strong M.J., Kesavapany S., Pant H.C. The pathobiology of amyotrophic lateral sclerosis: a proteinopathy?. J. Neuropathol. Exp. Neurol. 2005, 64:649-664.
221. Tagashira H., Shinoda Y., Shioda N., Fukunaga K. Methyl pyruvate rescues mitochondrial damage caused by SIGMAR1 mutation related to amyotrophic lateral sclerosis. Biochim. Biophys. Acta 2014, 1840:3320-3334.
222. Tanaka K. The proteasome: from basic mechanisms to emerging roles. Keio J. Med. 2013, 62:1-12.
223. Tanigawa S., Fujii M., Hou D.X. Action of Nrf2 and Keap1 in ARE-mediated NQO1 expression by quercetin. Free Radic. Biol. Med. 2007, 42:1690-1703.
224. Taniguchi T., Garcia-Higuera I., Andreassen P.R., Gregory R.C., Grompe M., D'Andrea A.D. S-phase-specific interaction of the Fanconi anemia protein, FANCD2, with BRCA1 and RAD51. Blood 2002, 100:2414-2420.
225. Tashiro Y., Urushitani M., Inoue H., Koike M., Uchiyama Y., Komatsu M., Tanaka K., Yamazaki M., Abe M., Misawa H., Sakimura K., Ito H., Takahashi R. Motor neuron-specific disruption of proteasomes, but not autophagy, replicates amyotrophic lateral sclerosis. J. Biol. Chem. 2012, 287:42984-42994.
226. (2) stress in cell lines from patients with ataxia-telangiectasia. Oncogene 2002, 21:4363-4373.
227. Taylor R.C., Dillin A. Aging as an event of proteostasis collapse. Cold Spring Harb. Perspect. Biol. 2011, 3.
228. Thompson M.L., Chen P., Yan X., Kim H., Borom A.R., Roberts N.B., Caldwell K.A., Caldwell G.A. TorsinA rescues ER-associated stress and locomotive defects in C. elegans models of ALS. Dis. Models Mech. 2014, 7:233-243.
229. Tonoki A., Kuranaga E., Tomioka T., Hamazaki J., Murata S., Tanaka K., Miura M. Genetic evidence linking age-dependent attenuation of the 26S proteasome with the aging process. Mol. Cell. Biol. 2009, 29:1095-1106.
230. Trippier P.C., Zhao K.T., Fox S.G., Schiefer I.T., Benmohamed R., Moran J., Kirsch D.R., Morimoto R.I., Silverman R.B. Proteasome activation is a mechanism for pyrazolone small molecules displaying therapeutic potential in amyotrophic lateral sclerosis. ACS Chem. Neurosci. 2014, 5:823-829.
231. Tsai Y.C., Fishman P.S., Thakor N.V., Oyler G.A. Parkin facilitates the elimination of expanded polyglutamine proteins and leads to preservation of proteasome function. J. Biol. Chem. 2003, 278:22044-22055.
232. Tseng B.P., Green K.N., Chan J.L., Blurton-Jones M., LaFerla F.M. Abeta inhibits the proteasome and enhances amyloid and tau accumulation. Neurobiol. Aging 2008, 29:1607-1618.
233. Tsuji S., Kikuchi S., Shinpo K., Tashiro J., Kishimoto R., Yabe I., Yamagishi S., Takeuchi M., Sasaki H. Proteasome inhibition induces selective motor neuron death in organotypic slice cultures. J. Neurosci. Res. 2005, 82:443-451.
234. Tullet J.M., Hertweck M., An J.H., Baker J., Hwang J.Y., Liu S., Oliveira R.P., Baumeister R., Blackwell T.K. Direct inhibition of the longevity-promoting factor SKN-1 by insulin-like signaling in C. elegans. Cell 2008, 132:1025-1038.
235. Um J.W., Im E., Lee H.J., Min B., Yoo L., Yoo J., Lubbert H., Stichel-Gunkel C., Cho H.S., Yoon J.B., Chung K.C. Parkin directly modulates 26S proteasome activity. J. Neurosci. 2010, 30:11805-11814.
236. Unnithan A.S., Jiang Y., Rumble J.L., Pulugulla S.H., Posimo J.M., Gleixner A.M., Leak R.K. N-acetyl cysteine prevents synergistic, severe toxicity from two hits of oxidative stress. Neurosci. Lett. 2014, 560:71-76.
237. Uno M., Honjoh S., Matsuda M., Hoshikawa H., Kishimoto S., Yamamoto T., Ebisuya M., Yamamoto T., Matsumoto K., Nishida E. A fasting-responsive signaling pathway that extends life span in C. elegans. Cell Rep. 2013, 3:79-91.
238. Urushitani M., Kurisu J., Tsukita K., Takahashi R. Proteasomal inhibition by misfolded mutant superoxide dismutase 1 induces selective motor neuron death in familial amyotrophic lateral sclerosis. J. Neurochem. 2002, 83:1030-1042.
239. Vachova L., Cap M., Palkova Z. Yeast colonies: a model for studies of aging, environmental adaptation, and longevity. Oxid. Med. Cell. Longev. 2012, 2012:601836.
240. Valera E., Dargusch R., Maher P.A., Schubert D. Modulation of 5-lipoxygenase in proteotoxicity and Alzheimer's disease. J. Neurosci.: Off. J. Soc. Neurosci. 2013, 33:10512-10525.
241. van Leeuwen F.W., de Kleijn D.P., van den Hurk H.H., Neubauer A., Sonnemans M.A., Sluijs J.A., Koycu S., Ramdjielal R.D., Salehi A., Martens G.J., Grosveld F.G., Peter J., Burbach H., Hol E.M. Frameshift mutants of beta amyloid precursor protein and ubiquitin-B in Alzheimer's and Down patients. Science (New York, NY) 1998, 279:242-247.
242. van Leeuwen F.W., van Tijn P., Sonnemans M.A., Hobo B., Mann D.M., Van Broeckhoven C., Kumar-Singh S., Cras P., Leuba G., Savioz A., Maat-Schieman M.L., Yamaguchi H., Kros J.M., Kamphorst W., Hol E.M., de Vos R.A., Fischer D.F. Frameshift proteins in autosomal dominant forms of Alzheimer disease and other tauopathies. Neurology 2006, 66:S86-S92.
243. Vantyghem M.C., Balavoine A.S., Douillard C., Defrance F., Dieudonne L., Mouton F., Lemaire C., Bertrand-Escouflaire N., Bourdelle-Hego M.F., Devemy F., Evrard A., Gheerbrand D., Girardot C., Gumuche S., Hober C., Topolinski H., Lamblin B., Mycinski B., Ryndak A., Karrouz W., Duvivier E., Merlen E., Cortet C., Weill J., Lacroix D., Wemeau J.L. How to diagnose a lipodystrophy syndrome. Ann. Endocrinol. (Paris) 2012, 73:170-189.
244. Vernace V.A., Arnaud L., Schmidt-Glenewinkel T., Figueiredo-Pereira M.E. Aging perturbs 26S proteasome assembly in Drosophila melanogaster. FASEB J. 2007, 21:2672-2682.
245. Vilchez D., Boyer L., Morantte I., Lutz M., Merkwirth C., Joyce D., Spencer B., Page L., Masliah E., Berggren W.T., Gage F.H., Dillin A. Increased proteasome activity in human embryonic stem cells is regulated by PSMD11. Nature 2012, 489:304-308.
246. Vilchez D., Morantte I., Liu Z., Douglas P.M., Merkwirth C., Rodrigues A.P., Manning G., Dillin A. RPN-6 determines C. elegans longevity under proteotoxic stress conditions. Nature 2012, 489:263-268.
247. Viswanathan A., Greenberg S.M. Cerebral amyloid angiopathy in the elderly. Ann. Neurol. 2011, 70:871-880.
248. Viteri G., Chung Y.W., Stadtman E.R. Effect of progerin on the accumulation of oxidized proteins in fibroblasts from Hutchinson Gilford progeria patients. Mech. Ageing Dev. 2010, 131:2-8.
249. Wade B.E., Wang C.E., Yan S., Bhat K., Huang B., Li S., Li X.J. Ubiquitin-activating enzyme activity contributes to differential accumulation of mutant huntingtin in brain and peripheral tissues. J. Neurosci.: Off. J. Soc. Neurosci. 2014, 34:8411-8422.
250. Walker F.O. Huntington's disease. Lancet 2007, 369:218-228.
251. Wang H., Megill A., He K., Kirkwood A., Lee H.K. Consequences of inhibiting amyloid precursor protein processing enzymes on synaptic function and plasticity. Neural Plas. 2012, 2012:272374.
252. Wang J., Wang C.E., Orr A., Tydlacka S., Li S.H., Li X.J. Impaired ubiquitin-proteasome system activity in the synapses of Huntington's disease mice. J. Cell Biol. 2008, 180:1177-1189.
253. Wang L., Mao X., Ju D., Xie Y. Rpn4 is a physiological substrate of the Ubr2 ubiquitin ligase. J. Biol. Chem. 2004, 279:55218-55223.
254. Worman H.J., Bonne G. Laminopathies: a wide spectrum of human diseases. Exp. Cell Res. 2007, 313:2121-2133.
255. Worman H.J., Ostlund C., Wang Y. Diseases of the nuclear envelope. Cold Spring Harb. Perspect. Biol. 2010, 2:a000760.
256. Wu J., Huen M.S., Lu L.Y., Ye L., Dou Y., Ljungman M., Chen J., Yu X. Histone ubiquitination associates with BRCA1-dependent DNA damage response. Mol. Cell. Biol. 2009, 29:849-860.
257. Yamamoto A., Lucas J.J., Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 2000, 101:57-66.
258. Yang E.J., Kim S.H., Yang S.C., Lee S.M., Choi S.M. Melittin restores proteasome function in an animal model of ALS. J. Neuroinflamm. 2011, 8:69.
259. Yang H., Zhong X., Ballar P., Luo S., Shen Y., Rubinsztein D.C., Monteiro M.J., Fang S. Ubiquitin ligase Hrd1 enhances the degradation and suppresses the toxicity of polyglutamine-expanded huntingtin. Exp. Cell Res. 2007, 313:538-550.
260. Yin J., Kwon Y.T., Varshavsky A., Wang W. RECQL4, mutated in the Rothmund-Thomson and RAPADILINO syndromes, interacts with ubiquitin ligases UBR1 and UBR2 of the N-end rule pathway. Hum. Mol. Genet. 2004, 13:2421-2430.
261. Yonashiro R., Sugiura A., Miyachi M., Fukuda T., Matsushita N., Inatome R., Ogata Y., Suzuki T., Dohmae N., Yanagi S. Mitochondrial ubiquitin ligase MITOL ubiquitinates mutant SOD1 and attenuates mutant SOD1-induced reactive oxygen species generation. Mol. Biol. Cell 2009, 20:4524-4530.
262. Yong-Kee C.J., Salomonczyk D., Nash J.E. Development and validation of a screening assay for the evaluation of putative neuroprotective agents in the treatment of Parkinson's disease. Neurotox. Res. 2011, 19:519-526.
263. Yun C., Stanhill A., Yang Y., Zhang Y., Haynes C.M., Xu C.F., Neubert T.A., Mor A., Philips M.R., Ron D. Proteasomal adaptation to environmental stress links resistance to proteotoxicity with longevity in Caenorhabditis elegans. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:7094-7099.
264. Zaiss D.M., Standera S., Holzhutter H., Kloetzel P., Sijts A.J. The proteasome inhibitor PI31 competes with PA28 for binding to 20S proteasomes. FEBS Lett. 1999, 457:333-338.
265. Zaremba-Czogalla M., Dubinska-Magiera M., Rzepecki R. Laminopathies: the molecular background of the disease and the prospects for its treatment. Cell. Mol. Biol. Lett. 2011, 16:114-148.
266. Zhang Z., Li X., Xie W.J., Tuo H., Hintermann S., Jankovic J., Le W. Anti-parkinsonian effects of Nurr1 activator in ubiquitin-proteasome system impairment induced animal model of Parkinson's disease. CNS Neurol. Disord. Drug Targ. 2012, 11:768-773.